Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608712 | 0.88 | SMN1; SMN2 (0.39) | MAPTNR2F2HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3615832 | 0.85 | SMN1; SMN2 (0.37) | MAPTNR2F2HTTSMN1; SMN2 | |
| SCHEMBL3615837 | 0.85 | SMN1; SMN2 (0.37) | MAPTNR2F2HTTSMN1; SMN2 | |
| SCHEMBL3614211 | 0.82 | HPGD (0.33) | MAPTL3MBTL1 | |
| SCHEMBL3602203 | 0.81 | NPC1 (0.31) | SMN1; SMN2 | |
| SCHEMBL3606716 | 0.77 | ALDH1A1 (0.37) | MAPTNR2F2HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3596945 | 0.77 | TDP1 (0.41) | L3MBTL1 | |
| SCHEMBL3610097 | 0.73 | SMN1; SMN2 (0.39) | MAPTNR2F2HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3607161 | 0.72 | SMN1; SMN2 (0.40) | MAPTNR2F2HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL3617878 | 0.70 | HSD17B2 (0.36) | MAPTHTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | MAPT 3754/4885NR2F2 3834/4885HTT 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.